University of Worcester Worcester Research and Publications

Can BCAT1 Expression Level Help Predict Disease Progression in Chronic Lymphocytic Leukaemia

Coles, Steven ORCID: and Wadley, Alex (2017) Can BCAT1 Expression Level Help Predict Disease Progression in Chronic Lymphocytic Leukaemia. Cancer and Oncology: Open Access Journal, 1 (1).

cooaj_01_01_00001.pdf - Published Version
Available under License Creative Commons Attribution.

Download (812kB) | Preview


Chronic lymphocytic leukaemia (CLL) is the most common blood
cancer in the UK, with an incidence of >3500 newly diagnosed
cases per year resulting in >1000 deaths. Disease prevalence
increases with age, where the majority of patients are >65 years
old [1]. CLL is a largely indolent disease and is routinely staged
according to the Binet system as follows; stage A (involving
0-2 lymphoid sites), stage B (involving 2-5 lymphoid cites) and
stage C (platelets < 1x1011/L or haemoglobin <10g/dL), the
latter stage reflecting loss of bone marrow function [2]. Whilst
for some stage A patients, the disease may remain stable for
many decades (median life expectancy of 13 years), for others
the disease progresses more rapidly [3]. This observation likely
reflects the genetic and molecular heterogeneity of CLL. As such
there are several prognostic risk factors used to stratify newly
diagnosed patients, which include; trisomy-12, 13q/17p/11q23
deletion, advanced stage, males>females, unmutated VH Ig
genes, raised lactate dehydrogenase activity and expression
of Zap70 and CD38 [4]. CLL is traditionally treated with a
combination of chemotherapeutic reagents, namely, Fludarabine/
Cyclophosphamide/Rituximab (FCR), however treatment remains
challenging within the elderly population [1]. Lately the Brutan’s
tyrosine kinase inhibitor, Ibrutinib, has shown great promise for
the treatment of CLL [5]. However, exceptions are identified as
well as treatment resistance prompting further research into CLL
treatment strategies [6].

Item Type: Article
Additional Information:

The full-text of the online published article can be accessed via the Official URL.
Copyright© 2018 Coles et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and source are credited.

Uncontrolled Discrete Keywords: CLL, lymphocyte, prognosis, oncogenesis, metabolism
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: College of Health, Life and Environmental Sciences > School of Science and the Environment
Related URLs:
Copyright Info: Open Access article (UW LS APC)
Depositing User: Steven Coles
Date Deposited: 22 Nov 2017 08:56
Last Modified: 17 Jun 2020 17:20

Actions (login required)

View Item View Item
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.